SCHEDULE: Cormorant Asset Management Boosts Cabaletta Bio Stake

Cormorant Asset Management and Bihua Chen report a 9.28% beneficial ownership stake in Cabaletta Bio, Inc., including shares from warrants.

Summary

• Cormorant Asset Management, LP and Bihua Chen collectively report beneficial ownership of 9,400,000 shares of Cabaletta Bio, Inc. common stock.
• This represents 9.28% of the company's outstanding common stock.
• The reported holdings include shares issuable upon the exercise of warrants, which are exercisable for up to 5,000,000 shares of common stock.
• The percentage is calculated based on 96,265,204 shares outstanding as of October 31, 2025, as reported in Cabaletta Bio's Form 10-Q.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial stake by a specialized investment firm like Cormorant Asset Management suggests a vote of confidence in Cabaletta Bio's prospects.

Positives

• A significant stake (9.28%) held by an institutional investment adviser like Cormorant Asset Management may signal confidence in Cabaletta Bio's long-term prospects.
• The inclusion of warrants suggests a potential for increased ownership and continued interest in the company's future.

Future Outlook

This filing does not provide forward-looking statements or guidance from the issuer.

Industry Context

StockSavvy.ai notes that significant institutional ownership, particularly from specialized healthcare investors like Cormorant Asset Management, can often be interpreted as a positive signal for a biotechnology company like Cabaletta Bio. Such investors typically conduct extensive due diligence on a company's pipeline, management, and market potential before taking a substantial stake.

Comparison to Industry Standards

• A 9.28% stake by an institutional investor is a substantial position, indicating a high conviction investment.
• While direct comparisons to specific companies or projects are not provided in this filing, such a large holding by a specialized fund like Cormorant Asset Management, which focuses on healthcare, suggests a belief in Cabaletta Bio's potential within the competitive biotechnology landscape.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a nearly 10% stake could instill confidence and potentially attract further investor interest, positively impacting share value.

Key Dates

Recommendation

While the significant stake by Cormorant Asset Management is a positive signal, this filing is purely an ownership disclosure and does not provide new operational or financial performance data. A "hold" recommendation reflects the positive sentiment from institutional backing without new fundamental catalysts for a "buy" or "strong buy" based solely on this filing. Investors should consider this alongside other fundamental analysis.

Keywords

Cabaletta Bio, Cormorant Asset Management, Bihua Chen, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Institutional Investor, Biotechnology, Healthcare